Use of biologic response modifiers for the management of ocular inflammatory conditions
Ocular inflammatory conditions can be challenging to manage due to their prolonged and complicated nature. While the mainstay treatment for most cases is oral or topical corticosteroids, it is very important that physicians know how other medications such as biologic response modifiers (biologics) c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2018;volume=13;issue=4;spage=259;epage=263;aulast=Rivera-Grana |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544410709000192 |
|---|---|
| author | Erick Rivera-Grana Jay Siak James T Rosenbaum |
| author_facet | Erick Rivera-Grana Jay Siak James T Rosenbaum |
| author_sort | Erick Rivera-Grana |
| collection | DOAJ |
| description | Ocular inflammatory conditions can be challenging to manage due to their prolonged and complicated nature. While the mainstay treatment for most cases is oral or topical corticosteroids, it is very important that physicians know how other medications such as biologic response modifiers (biologics) could be used in certain cases. Through illustrative cases, we discuss how treatment with biologics can be helpful in the management of three challenging patients with ocular inflammatory conditions. We review and discuss, (1) a 60-year-old male with granulomatosis with polyangiitis and bilateral anterior scleritis who required rituximab; (2) a 25-year-old male with refractory, idiopathic, bilateral chronic panuveitis and retinal vasculitis, which was controlled with adalimumab after treatment failure with oral and topical corticosteroids, cyclosporine, and methotrexate; and (3) a 44-year-old female with unilateral blindness and juvenile psoriatic arthritis-related intermediate uveitis, who required adalimumab to control her complication of persistent macular edema. These cases highlight the considerations that are required when clinicians are faced with the need to commence biologic therapy for patients with refractory ocular inflammation. |
| format | Article |
| id | doaj-art-72ad2c853b5f4d6080b0111cf5400016 |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-72ad2c853b5f4d6080b0111cf54000162025-02-03T10:23:13ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012018-01-0113425926310.4103/injr.injr_83_18Use of biologic response modifiers for the management of ocular inflammatory conditionsErick Rivera-GranaJay SiakJames T RosenbaumOcular inflammatory conditions can be challenging to manage due to their prolonged and complicated nature. While the mainstay treatment for most cases is oral or topical corticosteroids, it is very important that physicians know how other medications such as biologic response modifiers (biologics) could be used in certain cases. Through illustrative cases, we discuss how treatment with biologics can be helpful in the management of three challenging patients with ocular inflammatory conditions. We review and discuss, (1) a 60-year-old male with granulomatosis with polyangiitis and bilateral anterior scleritis who required rituximab; (2) a 25-year-old male with refractory, idiopathic, bilateral chronic panuveitis and retinal vasculitis, which was controlled with adalimumab after treatment failure with oral and topical corticosteroids, cyclosporine, and methotrexate; and (3) a 44-year-old female with unilateral blindness and juvenile psoriatic arthritis-related intermediate uveitis, who required adalimumab to control her complication of persistent macular edema. These cases highlight the considerations that are required when clinicians are faced with the need to commence biologic therapy for patients with refractory ocular inflammation.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2018;volume=13;issue=4;spage=259;epage=263;aulast=Rivera-GranaBiologicsscleritisuveitis |
| spellingShingle | Erick Rivera-Grana Jay Siak James T Rosenbaum Use of biologic response modifiers for the management of ocular inflammatory conditions Indian Journal of Rheumatology Biologics scleritis uveitis |
| title | Use of biologic response modifiers for the management of ocular inflammatory conditions |
| title_full | Use of biologic response modifiers for the management of ocular inflammatory conditions |
| title_fullStr | Use of biologic response modifiers for the management of ocular inflammatory conditions |
| title_full_unstemmed | Use of biologic response modifiers for the management of ocular inflammatory conditions |
| title_short | Use of biologic response modifiers for the management of ocular inflammatory conditions |
| title_sort | use of biologic response modifiers for the management of ocular inflammatory conditions |
| topic | Biologics scleritis uveitis |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2018;volume=13;issue=4;spage=259;epage=263;aulast=Rivera-Grana |
| work_keys_str_mv | AT erickriveragrana useofbiologicresponsemodifiersforthemanagementofocularinflammatoryconditions AT jaysiak useofbiologicresponsemodifiersforthemanagementofocularinflammatoryconditions AT jamestrosenbaum useofbiologicresponsemodifiersforthemanagementofocularinflammatoryconditions |